Public Comment Closes on the FDA Plan to Permanently Bar Bulk Compounding of Semaglutide and Tirzepatide

The comment window on FDA’s proposal to keep semaglutide and tirzepatide off the 503B bulk list closed July 30. No final decision has been announced.

Have A Referral?